|本期目录/Table of Contents|

[1]管晓音,孙文明,赵春花,等.超快速液相色谱法研究厄贝沙坦的药代动力学[J].医学研究与战创伤救治(原医学研究生学报),2010,12(02):102.
　GUAN Xiao-yin,SUN Wen-ming,ZHAO Chun-hua,et al.Pharmacokinetic studies of irbesartan in beagle dog plasma by ultra-fast liquid chromatography[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2010,12(02):102.
点击复制

超快速液相色谱法研究厄贝沙坦的药代动力学()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第12卷
期数:
2010年02期
页码:
102
栏目:
出版日期:
2010-03-20

文章信息/Info

Title:
Pharmacokinetic studies of irbesartan in beagle dog plasma by ultra-fast liquid chromatography
文章编号:
1672-271X(2010)02-0102-03
作者:
管晓音1; 孙文明2; 赵春花1; 周玉梅3
1.212003 江苏镇江,镇江陆军船艇学院门诊部；2.210016 江苏南京,南京军区联勤部卫生部；3.212003 江苏镇江，江苏大学附属医院
Author(s):
GUAN Xiao-yin1;  SUN Wen-ming2;  ZHAO Chun-hua1;  ZHOU Yu-mei3.
1. Clinic, Zhengjiang Watercraft College，Zhengjiang, Jiangsu 212003，China； 2. Division of Health, Department of Joint Logistics, Nanjing Military Command， PLA， Nanjing, Jiangsu 210016，China；3. Affiliated Hospital of Jiangsu University, Zhengjiang, Jiangs
关键词:
厄贝沙坦; 超快速液相色谱; 药代动力学
Keywords:
irbesartan;  ultra-fast liquid chromatography;  pharmacokinetics
分类号:
R943
DOI:
-
文献标志码:
A
摘要:
目的 研究厄贝沙坦在比格犬体内的药代动力学。方法 给比格犬口服厄贝沙坦片，用超快速液相色谱法检测厄贝沙坦的浓度。结果 主要药代动力学参数如半衰期、峰浓度、AUC0~48分别为：(13.96 ± 3.26) h、(2582.85 ± 1265.69 ) ng/ml、(7951.13 ± 2794.07)ng·h/ml。结论 该方法灵敏、准确，能快速检测比格犬血浆中厄贝沙坦浓度。
Abstract:
Objective To analyze the pharmacokinetics of irbesartan tablet in beagle dogs. Methods Six healthy subjects received a single oral dose of 300 mg irbesartan tablet. The plasma concentrations of irbesartan were determined using ultra-fast liquid chromatography. Results The main pharmacokinetics parameters of irbesartan were: t1/2 13.96 ± 3.26 h, Cmax 2582.85 ± 1265.69 ng/ml, AUC0~48 7951.13 ±2794.07 ng·h/ml. Conclusion The method established in this study allows for highly sensitive, selective and accurate determination of plasma concentration of plasma irbesartan in dogs.

参考文献/References:

[1]江培霞. 浅析厄贝沙坦的临床应用与疗效［J］. 医学理论与实践, 2008, 21(8): 906-907.
[2］陈文丽. 厄贝沙坦对原发性高血压的疗效观察［J］. 中国实用医刊, 2008, 35(17): 79.
[3］黄晓晖,裘福荣,李 俊. 厄贝沙坦在健康志愿者体内的药代动力学-药效学结合模型［J］. 中国药理学通报, 2005, 21(6): 712-715.
[4］Chang SY, Whigan DB, Vachharajani NN, et al. High-performance liquid chromatographic assay for the quantitation of irbesartan (SR 47436/BMS-186295) in human plasma and urine ［J］. J Chromatogr B Biomed Sci Appl, 1997, 702(1-2): 149-155.
[5］Nevin Erk. Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by liquid chromatography ［J］. J Chromatogr B, 2003, 784(9): 195-201.
[6］丁一冰, 樊夏雷, 沈建平. Cap-HPLC测定人血浆中厄贝沙坦和氢氯噻嗪浓度及其复方制剂的生物等效性研究［J］. 中国药科大学学报, 2005, 36(6): 551-555.
[7］Ferreiros N, Iriarte G, Alonso RM, et al. Development of a solid phase extraction procedure for HPLC-DAD determination of several angiotensin Ⅱ receptor antagonists in human urine using mixture design ［J］. Talanta, 2007, 73(5): 748-756.
[8］Jing N, Min Z, Yi F, et al. Biocompatible in-tube solid-phase microextraction coupled to HPLC for the determination of angiotensin Ⅱ receptor antagonists in human plasma and urine ［J］. J Chromatogr B, 2005, 828(10): 62-69.
[9］Ashok KS, Yusuf MA, Omran MOA. Liquid chromatographic determination of irbesartan in human plasma ［J］. J Chromatogr B, 2007, 848(11): 245-250.

相似文献/References:

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2010-03-20